Novartis acquires Mariana in $1.75bn deal to strengthen ... - MSN

Novartis will acquire Mariana’s lead candidate MC-339, a radioligand therapy (RLT) designed to target small-cell lung cancer. Last year, Mariana had raised $175m in a Series B round from …

CouponFollow Extension

$1.75
OFF

Novartis Acquires Mariana In $1.75bn Deal To Strengthen ... - MSN

4 weeks from now

Novartis will acquire Mariana’s lead candidate MC-339, a radioligand therapy (RLT) designed to target small-cell lung cancer. Last year, Mariana had raised $175m in a Series B round from …

msn.com

$1.75
OFF

Novartis To Acquire Radiopharmaceutical Firm Mariana Oncology …

4 weeks from now

May 3, 2024 · Novartis on Thursday announced plans to acquire radiopharmaceutical firm Mariana Oncology for up to $1.75 billion. The Swiss drugmaker said the deal will bolster its …

radiologybusiness.com

$1.75
OFF

Novartis To Buy Mariana Oncology For Up To $1.75 Billion In Boost …

4 weeks from now

May 2, 2024 · Novartis agreed to acquire U.S. biotechnology company Mariana Oncology for up to $1.75 billion, in a deal that bolsters its radioligand therapy pipeline and efforts to develop …

morningstar.com

$1
OFF

Novartis To Buy Mariana Oncology In Radiopharmaceutical Expansion

4 weeks from now

May 2, 2024 · Novartis is expanding its pipeline of radiopharmaceutical drugs, announcing Thursday it has agreed to pay $1 billion to acquire biotechnology company Mariana Oncology.

yahoo.com

$1.75
OFF

Novartis To Acquire Mariana For Up To $1.75B, Expanding …

4 weeks from now

May 2, 2024 · Novartis has agreed to acquire Mariana Oncology for up to $1.75 billion, the companies said today, in a deal that would further expand the buyer’s radiopharmaceutical …

genengnews.com

$1
OFF

Forbion Portfolio Company Mariana Oncology To Be Acquired By …

4 weeks from now

May 2, 2024 · • Latest deal marks the fifth Forbion portfolio company to be acquired for over $1 bn within a year. Naarden, The Netherlands, 2 May 2024 - Forbion portfolio company Mariana …

forbion.com

$1
OFF

Novartis Entrenches Into Radiopharma With $1B Mariana Buy

4 weeks from now

May 2, 2024 · With Novartis’ existing radioligand pipeline featuring Pluvicto and Lutathera and the Big Pharma model of taking drugs to market, Mariana CEO Simon Read, Ph.D., said the deal …

fiercebiotech.com

$1
OFF

Novartis To Buy Mariana Oncology, Paying $1 Billion Upfront

4 weeks from now

May 2, 2024 · Novartis agreed to buy US biotech Mariana Oncology Inc. to strengthen its pipeline of drugs that can specifically target cancer cells. The Swiss company said Bloomberg Terminal

bloomberg.com

FAQs about Novartis acquires Mariana in $1.75bn deal to strengthen ... - MSN Coupon?

Does Novartis own Mariana oncology?

Basel, May 2, 2024 – Novartis today announced that it has entered into an agreement to acquire Mariana Oncology, a preclinical-stage biotechnology company based in Watertown, Massachusetts focused on developing novel radioligand therapies (RLTs) to treat cancers with high unmet patient need. ...

How much money will Mariana get from Novartis?

Mariana, which specializes in the targeted radiation medicines, could receive up to $750 million more from Novartis if certain milestones are met. The deal hands Novartis several drug programs, including one candidate being tested as a treatment for small cell lung cancer. ...

What's the difference between Novartis and Mariana?

Novartis’ Pluvicto and Lutathera are approved for prostate cancer and neuroendocrine tumors, respectively, while Mariana’s pipeline tackles a wider range of tumor types and targets. While peers like Lilly have been focused on bulking up the manufacturing side of the business, Novartis’ interest in Mariana was more around innovation. ...

Should a biotech choose Novartis or Mariana?

While Mariana had a neatly planned pipeline, Read said a biotech always has to pick and choose the programs carefully based on financing, head count and other factors. With the weight of Novartis, the biotech can take a broader range of ideas forward and ultimately reach more patients than it ever could have alone. ...

Who owns Mariana biotech?

Mariana was founded in 2021 with fundraising from Atlas Venture, Access Biotechnology and RA Capital Management. Eli Lilly was another early investor. The biotech’s lead program is MC-339, which is being developed in small cell lung cancer. The deal also includes $750 million in milestones, although Read was mum on exactly what would trigger them. ...

Does Novartis need a big move?

The CEO said the biotech didn’t need to make a big move like this after raising $175 million late last year in a series B, but Mariana had caught the attention of potential buyers. Novartis had recently been joined by peers Lilly and Bristol Myers Squibb in the radiopharmaceuticals space with plenty of deal action. ...